Mexico Cuts Clinical Trial Approval Times From 120 to 30 Days, Unlocking US$643 Million in Pharma Investment
核心洞察
Mexico's COFEPRIS (搜索) has reduced clinical trial approval times from 120 to 30 days, announced at Scientific Conference 2026 as part of a national research and innovation agenda.
The regulatory reform has coincided with more than US$643 million in new pharmaceutical investment from Boehringer Ingelheim, Bayer (搜索), AstraZeneca, and Camber-Amarox (搜索) over the past 14 months.
Minister of Health David Kershenobich outlined a three-pillar program focused on regulatory improvement, investment attraction, and pharmaceutical sovereignty under the Plan México framework.
Mexico's Federal Commission for Protection against Health Risks (COFEPRIS (搜索)) has cut clinical trial approval times from 120 to 30 days, a regulatory shift announced at Scientific Conference 2026 that has coincided with more than US$643 million in new pharmaceutical investment and is reshaping the country's position as a clinical research destination in Latin America.
The announcement was made during Scientific Conference 2026, organized by the Coordinating Commission of National Institutes of Health and High Specialty Hospitals (CCINSHAE) and held in Mexico City. The high-level forum brought together health institutions, regulatory bodies, academia, the pharmaceutical industry, and the scientific community to establish a shared agenda aimed at translating knowledge generated in laboratories and specialized institutes into clinical interventions with direct impact on patients.
A Three-Pillar Research Agenda
Minister of Health David Kershenobich outlined a three-pillar research program built around regulatory improvement, institutional coordination, and investment attraction. The first pillar is regulatory improvement, under which COFEPRIS (搜索) reduced authorization timelines for clinical research protocols from 120 days to about 30 days. This trajectory has been building since mid-2025: in May 2025, COFEPRIS announced as part of Plan México a 65% reduction in response times for clinical protocols — from 115 to 40 days — with a stated goal of reaching a two-week turnaround. The agency also signed agreements with the Mexican Institute of Industrial Property (IMPI) that reduced the time required to link patents with sanitary registrations from several months to five days.
The second pillar is attracting clinical research investment, with a focus on high-prevalence diseases. Kershenobich says the government seeks to increase Mexico's participation in international multicenter studies, particularly in oncology, endocrinology, and infectious diseases. The third pillar is pharmaceutical sovereignty, defined as strengthening national production and regulatory capacity to reduce dependence on imported inputs, a component that connects directly to the Plan México agenda.
Institutional Coordination Under Plan México
COFEPRIS (搜索), the National Center for Research and Health Evaluation, and the National Commission of Bioethics have operated a Permanent Interinstitutional Board for Clinical Protocols since January 2026, coordinating ethics and regulatory review under the Plan México framework. The board's function is procedural, but its effect is commercial: shorter authorization timelines lower the cost of running trials in Mexico relative to competing Latin American markets, a variable that directly informs where multinational pharmaceutical companies locate research infrastructure.
On the regulatory side, the framework underpinning these improvements has been formalized through international alignment. COFEPRIS (搜索) implemented a Regulatory Reliance agreement that recognizes evaluations conducted by the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada to expedite the approval of clinical research protocols.
Capital Follows the Approval Timeline
Over the past 14 months, international and domestic pharmaceutical companies have committed more than US$643 million to expand manufacturing and research operations across Mexico, and executives cite regulatory speed as a recurring factor behind those decisions.
Manuel Bravo, President of Bayer (搜索), made that link explicit when discussing the company's investment plans. COFEPRIS (搜索)'s faster permitting, he says, "allows the company to triple its investment in Mexican clinical studies," directly connecting the regulatory change to a specific capital allocation decision rather than a general expression of confidence.
Boehringer Ingelheim committed MX$3.5 billion to expand its Xochimilco plant into the company's largest global site for tablet production, with capacity for 5 billion tablets annually supplying more than 40 international markets alongside the domestic one. Bayer (搜索) allocated a matching MX$3.5 billion to expand active pharmaceutical ingredient production at its Orizaba plant in Veracruz and add new lines at its Lerma facility in the State of Mexico, with output destined for local, North American, and European markets. AstraZeneca pledged more than MX$2.5 billion over two years, structured in three segments beginning with clinical research conducted across Mexico's top research institutes.
Government estimates put the combined job impact of this investment wave at more than 3,000 direct positions requiring specialized skills and over 20,000 indirect jobs across multiple regions. Kershenobich frames the pattern as evidence of investor confidence in the administration's health strategy, saying the commitments will "strengthen the country's health sovereignty, boost local production of essential medicines."
Nearshoring Adds a Second Layer
The regulatory and investment story intersects with a broader nearshoring trend already reshaping Mexico's manufacturing base. Camber-Amarox (搜索) opened a new plant in Morelos, housed in the former Nissan CIVAC industrial complex, with a US$50 million investment to produce essential medicines. The facility adds domestic production capacity with COFEPRIS (搜索) certification underway, reinforcing the government's stated goal of reducing reliance on imported active ingredients and finished pharmaceuticals.
This aligns with the broader positioning around Mexico's status as a pharmaceutical manufacturing hub, where proximity to the United States market, existing industrial infrastructure, and preferential trade terms under the USMCA combine with the newly compressed regulatory timeline to create a more complete value proposition than investment incentives alone could offer. The medical device sector is following a parallel track: the Mexican Association of Medical Device Industries has outlined plans to mobilize up to US$400 million in investment through 2030 under Plan México.
Disease Burden and Structural Friction
Mexico faces a growing disease burden. Chronic noncommunicable diseases, such as diabetes (搜索), hypertension (搜索), and cancer (搜索), represent the leading causes of mortality and hospitalization within the public system. According to the National Health and Nutrition Survey 2024, 29.9% of adults in Mexico live with hypertension. In this environment, clinical research carries a dual strategic value: it generates evidence on treatments and medical technologies adapted to local epidemiology, while also attracting foreign direct investment from pharmaceutical and medical device companies seeking markets with established scientific capacity and predictable regulatory frameworks.
However, the investment and regulatory momentum does not eliminate structural friction elsewhere in the health system. COFEPRIS (搜索)'s own market approval timeline for new products, distinct from the clinical trial process addressed at the Scientific Conference, has historically extended to around 60 working days, and industry voices have noted that lingering delays in other authorization categories can still discourage faster-moving investment decisions. The clinical trial reform addresses one bottleneck in a system with several.
Mexico's 2026 federal health budget rises 5.9% to MX$965 billion, driven mainly by increases for the Mexican Social Security Institute (IMSS) and IMSS-Bienestar, but analysts monitoring the sector note that funding remains below World Health Organization benchmarks relative to population needs. Private manufacturing investment and public health system financing are separate tracks, and growth in one does not automatically translate into capacity gains in the other.
For companies evaluating Mexico as a production or research base, the clearest signal from the past year is that regulatory reform and capital commitment are now moving in visible lockstep rather than on separate timelines. The 120-to-30-day compression in clinical trial approvals gave multinational pharmaceutical firms a concrete, measurable reason to accelerate previously discussed investment, and the resulting commitments indicate the change is already shaping capital allocation rather than merely improving sentiment. The open question for 2026 and beyond is whether the same institutional coordination model extends to the remaining approval categories that still run longer than the compressed clinical trial pathway.